MCID: EST001
MIFTS: 49

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060075

Summaries for Estrogen-Receptor Positive Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to tubular adenocarcinoma and mammographic density. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and GPCR Pathway. The drugs Fluorouracil and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 tubular adenocarcinoma 31.1 PGR ESR1 ERBB2
2 mammographic density 31.0 PGR ESR1 CYP19A1
3 papillary adenocarcinoma 30.9 TP53 PGR ERBB2
4 in situ carcinoma 30.6 TP53 PGR ESR1 ERBB2 BRCA1
5 fallopian tube carcinoma 30.3 TP53 PGR ESR1 ERBB2 BRCA1
6 sporadic breast cancer 30.3 TP53 PGR ESR1 ERBB2 BRCA1
7 estrogen-receptor negative breast cancer 30.2 PGR FOXA1 ESR1 ERBB2 BRCA1 AR
8 breast disease 30.1 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA1
9 female breast cancer 30.0 TP53 PGR ESR1 ERBB2 BRCA1 AR
10 breast adenocarcinoma 29.8 TP53 PIK3CA ESR1 ERBB2 AKT1
11 breast ductal carcinoma 29.6 TP53 PGR ESR1 ERBB2 CCND1 BRCA1
12 lung cancer susceptibility 3 29.6 TP53 PIK3CA ERBB2 CCND1 AKT1
13 adenocarcinoma 29.0 TP53 PIK3CA FGFR2 ERBB2 CCND1 AKT1
14 ductal carcinoma in situ 28.6 TP53 PGR ESR1 ERBB2 CYP19A1 CCND1
15 breast cancer 27.0 TP53 PIK3CA PGR NCOA3 MTOR FOXA1
16 endometrial cancer 26.7 TP53 PIK3CA PGR MTOR FGFR2 ESR1
17 bartholin's gland adenoma 10.7 PGR ESR1
18 vestibular gland benign neoplasm 10.7 PGR ESR1
19 breast apocrine carcinoma 10.7 PGR ERBB2
20 lung leiomyoma 10.7 PGR ESR1
21 vulvar syringoma 10.7 PGR ESR1
22 scirrhous adenocarcinoma 10.7 PGR ERBB2
23 endometrium carcinoma in situ 10.7 TP53 PGR
24 breast papillomatosis 10.7 ERBB2 CCND1
25 vulvar leiomyoma 10.7 PGR ESR1
26 trigonitis 10.7 PGR ESR1
27 vulvar benign neoplasm 10.7 PGR ESR1
28 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
29 glassy cell carcinoma of the cervix 10.6 PGR ESR1 ERBB2
30 intracystic papillary adenoma 10.6 PGR ERBB2
31 breast scirrhous carcinoma 10.6 PGR ESR1 ERBB2
32 tuberculous salpingitis 10.6 ERBB2 BRCA1
33 bartholin's duct cyst 10.6 TP53 AR
34 cancerophobia 10.6 PGR BRCA1
35 adult hepatocellular carcinoma 10.6 TP53 PIK3CA
36 breast metaplastic carcinoma 10.6 PGR ERBB2
37 non-proliferative fibrocystic change of the breast 10.6 TP53 ERBB2 CCND1
38 nosophobia 10.6 PGR BRCA1
39 cervical carcinosarcoma 10.6 TP53 PGR ESR1
40 inflammatory breast carcinoma 10.6 PGR ESR1 ERBB2
41 female reproductive endometrioid cancer 10.6 TP53 PGR ESR1
42 adenosarcoma 10.6 TP53 PGR ESR1
43 predominantly cortical thymoma 10.6 PGR ESR1
44 lipid-rich carcinoma 10.6 PGR ESR1 ERBB2
45 oncocytic breast carcinoma 10.6 PGR ESR1 AR
46 diffuse peritoneal leiomyomatosis 10.6 PGR ESR1 AR
47 microglandular adenosis 10.6 TP53 PGR ERBB2
48 mammary paget's disease 10.6 PGR ESR1 ERBB2
49 peritoneal benign neoplasm 10.6 PGR ESR1 AR
50 breast squamous cell carcinoma 10.6 TP53 PIK3CA ERBB2

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.05 MTOR PIK3CA
2 Decreased viability GR00107-A-1 10.05 HSPB8
3 Decreased viability GR00221-A-1 10.05 AKT1 ESR1 HSPB8 MTOR PIK3CA
4 Decreased viability GR00221-A-2 10.05 AKT1 ESR1 PIK3CA
5 Decreased viability GR00221-A-3 10.05 AKT1 ERBB2
6 Decreased viability GR00221-A-4 10.05 AKT1 ESR1 HSPB8 MTOR PIK3CA ERBB2
7 Decreased viability GR00301-A 10.05 HSPB8
8 Decreased viability GR00342-S-1 10.05 MTOR
9 Decreased viability GR00342-S-2 10.05 MTOR
10 Decreased viability GR00402-S-2 10.05 AKT1 ESR1 HSPB8 MTOR PIK3CA ERBB2

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.5 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
2 homeostasis/metabolism MP:0005376 10.48 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
3 behavior/neurological MP:0005386 10.46 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
4 endocrine/exocrine gland MP:0005379 10.45 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
5 cardiovascular system MP:0005385 10.42 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
6 growth/size/body region MP:0005378 10.41 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
7 immune system MP:0005387 10.41 AKT1 AR BRCA1 CCND1 CYP19A1 ESR1
8 mortality/aging MP:0010768 10.38 AKT1 AR BRCA1 CCND1 ERBB2 ESR1
9 integument MP:0010771 10.37 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
10 adipose tissue MP:0005375 10.36 AKT1 AR BRCA1 CYP19A1 ESR1 FGFR2
11 hematopoietic system MP:0005397 10.34 AKT1 AR BRCA1 CCND1 CYP19A1 ESR1
12 embryo MP:0005380 10.32 AKT1 AR BRCA1 ERBB2 ESR1 FGFR2
13 digestive/alimentary MP:0005381 10.29 AR BRCA1 CCND1 CYP19A1 ERBB2 ESR1
14 muscle MP:0005369 10.27 AKT1 AR BRCA1 CYP19A1 ERBB2 ESR1
15 neoplasm MP:0002006 10.21 AKT1 AR BRCA1 CCND1 ERBB2 ESR1
16 normal MP:0002873 10.18 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
17 liver/biliary system MP:0005370 10.15 AKT1 AR CYP19A1 ESR1 FGFR2 NCOA3
18 nervous system MP:0003631 10.14 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
19 limbs/digits/tail MP:0005371 10.05 AR BRCA1 ERBB2 ESR1 FGFR2 PGR
20 reproductive system MP:0005389 9.97 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
21 renal/urinary system MP:0005367 9.91 AR BRCA1 CYP19A1 ESR1 FGFR2 MTOR
22 pigmentation MP:0001186 9.72 AR BRCA1 CYP19A1 FGFR2 TP53
23 respiratory system MP:0005388 9.61 AKT1 BRCA1 CCND1 ERBB2 ESR1 FGFR2
24 skeleton MP:0005390 9.44 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3 51-21-8 3385
2
Epirubicin Approved Phase 3 56420-45-2 41867
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Norepinephrine Approved Phase 3 51-41-2 439260
5
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
6
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
7
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
8
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
9
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
10
Tamoxifen Approved Phase 3 10540-29-1 2733526
11
Metformin Approved Phase 3 657-24-9 4091 14219
12
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
13
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
14
Testosterone enanthate Approved Phase 3 315-37-7 9416
15
Methyltestosterone Approved Phase 3 58-18-4 6010
16
Testosterone Approved, Experimental, Investigational Phase 3 481-30-1, 58-22-0 6013 10204
17
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0
18
Sodium citrate Approved, Investigational Phase 3 68-04-2
19
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
20
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
21
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
22
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
23
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
24
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
25
Lenograstim Approved, Investigational Phase 3 135968-09-1
26
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
27
Lapatinib Approved, Investigational Phase 3 388082-78-8, 231277-92-2 208908 9941095
28
Palbociclib Approved, Investigational Phase 3 571190-30-2 5330286 11431660 5005498
29
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
30
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
32
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
33
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 5280795
34
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
36
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
37 Neurotransmitter Agents Phase 3
38 Omega 3 Fatty Acid Phase 3
39 Analgesics Phase 3
40 Peripheral Nervous System Agents Phase 3
41 Dopamine Agents Phase 3
42 Neurotransmitter Uptake Inhibitors Phase 3
43 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
44 Psychotropic Drugs Phase 3
45 Duloxetine Hydrochloride Phase 3
46 Antidepressive Agents Phase 3
47 Estrogens Phase 3
48 Steroid Synthesis Inhibitors Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Estrogen Receptor Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer. Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
3 ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
4 A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer Unknown status NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
5 Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment. Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
6 Ovarian Protection Trial In Premenopausal Breast Cancer Patients [OPTION] Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
7 A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal Patients With Primary Breast Cancer Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
8 A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer Completed NCT01598298 Phase 3 duloxetine hydrochloride
9 S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III Completed NCT01385137 Phase 3
10 A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
11 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
12 Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study Active, not recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
13 A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE) Active, not recruiting NCT02482753 Phase 3 Chidamide;exemestane;placebo
14 Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias Active, not recruiting NCT01573442 Phase 3 testosterone
15 International Breast Cancer Intervention Study Active, not recruiting NCT00078832 Phase 3 anastrozole;placebo
16 A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
17 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
18 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
19 A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer Active, not recruiting NCT00265759 Phase 3 anastrozole;exemestane;letrozole
20 A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
21 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer Active, not recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
22 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
23 Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B) Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
24 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
25 A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer Active, not recruiting NCT01349322 Phase 3
26 MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
27 A Randomized Controlled Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Enrolling by invitation NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
28 Efficacy, Tolerability, and Safety of Palbociclib Combined With an Aromatase Inhibitor in Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Locally Advanced Breast Cancer Not yet recruiting NCT04047758 Phase 3 Palbociclib + Letrozole;Letrozole
29 Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
30 Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
31 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
32 A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen Unknown status NCT01124695 Phase 2 tamoxifen citrate
33 Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
34 Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients Unknown status NCT00954135 Phase 2 letrozolo+cyclophosphamide;letrozolo+sorafenib+cyclophosphamide
35 A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer Unknown status NCT01142401 Phase 2 Bortezomib;Fulvestrant
36 Randomised Phase II Study of Metronomic Chemotherapy Plus the Same Aromatase Inhibitor Compared to Metronomic Chemotherapy Alone in Women With Hormone Receptor Positive, Her-2 Non-Overexpressing Advanced Breast Cancer Whose Disease Has Progressed While Receiving an Aromatase Inhibitor, Correlating Response With Circulating Endothelial Progenitor Cells, VEGF and VEGFR Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
37 A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer Unknown status NCT02216786 Phase 2 AZD2014;Everolimus;Fulvestrant
38 Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer. Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
39 Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer Unknown status NCT03192293 Phase 2 Metformin/Simvastatin/Fulvestrant
40 A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI) Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
41 A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0). Completed NCT00093002 Phase 2 Fulvestrant
42 A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women Completed NCT00107016 Phase 2 RAD001, Letrozole 2.5mg;Letrozole 2.5mg
43 Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
44 A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients Completed NCT01605396 Phase 2 Ridaforolimus;Dalotuzumab;Exemestane
45 Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy. Completed NCT02015559 Phase 2 mucoadhesive oral wound rinse
46 Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Completed NCT02988986 Phase 2 TAK-228;Tamoxifen
47 RED CLOVER EXTRACT (PROMENSIL) AND LIFESTYLE CHANGES TO CONTRAST MENOPAUSAL SYMPTOMS IN PREMENOPAUSAL WOMEN WITH HORMONE-SENSITIVE BREAST CANCER RECEIVING ADJUVANT ANTI-ESTROGEN THERAPY Completed NCT03844685 Phase 2 Promensil;Placebo Oral Tablet
48 A Single-arm Phase II Trial to Evaluate Serum Estradiol Levels in Patients With Breast Cancer Treated With Vaginal Estrogen, Estring Completed NCT01923298 Phase 2 Estradiol
49 A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
50 A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients With Oestrogen (ER) or Androgen Receptor (AR) Positive Advanced or Metastatic Breast Carcinoma Completed NCT00755885 Phase 1, Phase 2 abiraterone acetate

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

41
Breast, Bone, Lymph Node, Testes, Endothelial, Brain, Liver

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 1153)
# Title Authors PMID Year
1
Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells. 38
31117836 2019
2
Selective oestrogen receptor degraders in breast cancer: a review and perspectives. 38
31335829 2019
3
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26. 38
31199586 2019
4
Managing menopausal symptoms after cancer. 38
31433675 2019
5
Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production. 38
31406126 2019
6
Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer. 38
31403177 2019
7
27-Hydroxycholesterol enhanced osteoclastogenesis in lung adenocarcinoma microenvironment. 38
30511368 2019
8
Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. 38
31165373 2019
9
DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-positive Breast Cancer following endocrine therapy. 38
31387918 2019
10
Dysregulation of DNA methylation patterns may identify patients with breast cancer resistant to endocrine therapy: A predictive classifier based on differentially methylated regions. 38
31423189 2019
11
Hypofractionated radiation in older women with breast cancer. 38
31359556 2019
12
Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study. 38
30995175 2019
13
18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT. 38
31337657 2019
14
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. 38
31361400 2019
15
Polyphenolic natural products and natural product-inspired steroidal mimics as aromatase inhibitors. 38
30171625 2019
16
Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgical-only ER-positive breast cancer. 38
30537139 2019
17
CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer. 38
31384394 2019
18
Omission of radiation therapy following breast conservation in older (≥70 years) women with T1-2N0 triple-negative breast cancer. 38
31273872 2019
19
Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients. 38
31011525 2019
20
DC-SCRIPT deficiency delays mouse mammary gland development and branching morphogenesis. 38
31265831 2019
21
Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 38
30328052 2019
22
MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells. 38
30971760 2019
23
Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. 38
30259117 2019
24
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. 38
30943126 2019
25
HDL and LDL: Potential New Players in Breast Cancer Development. 38
31208017 2019
26
Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells. 38
31177399 2019
27
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. 38
31211741 2019
28
Joint pain and falls among women with breast cancer on aromatase inhibitors. 38
30306326 2019
29
Estrogen-mediated protection against coronary heart disease: The role of the Notch pathway. 38
30817989 2019
30
Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy. 38
31100952 2019
31
Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex. 38
30772267 2019
32
Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women. 38
30811755 2019
33
Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival. 38
31151151 2019
34
Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer. 38
31119683 2019
35
Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics. 38
31060537 2019
36
Recombinant Expression of Zinc Transporter SLC39A6 and Its Functional Antibody Production. 38
31009334 2019
37
Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors. 38
31037379 2019
38
Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. 38
30930994 2019
39
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. 38
30895900 2019
40
Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. 38
30707920 2019
41
Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling. 38
30941654 2019
42
Interaction between dietary acrylamide intake and genetic variants for estrogen receptor-positive breast cancer risk. 38
29445914 2019
43
21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. 38
30093354 2019
44
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer. 38
30824486 2019
45
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature. 38
30921233 2019
46
Overall and Estrogen Receptor-Positive Breast Cancer Incidences Are Decreased Following Bariatric Surgery. 38
30536017 2019
47
Bone health in women with breast cancer. 38
30896255 2019
48
High dimensional mediation analysis with latent variables. 38
30859548 2019
49
Removal of Serum Lipids and Lipid-Derived Metabolites to Investigate Breast Cancer Cell Biology. 38
30919589 2019
50
Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. 38
30865923 2019

Variations for Estrogen-Receptor Positive Breast Cancer

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.25 TP53 STAT5B PIK3CA PGR NCOA3 MTOR
2
Show member pathways
13.79 TP53 STAT5B NCOA3 FGFR2 ESR1 ERBB2
3
Show member pathways
13.61 TP53 STAT5B PIK3CA MTOR FGFR2 ERBB2
4
Show member pathways
13.48 TP53 STAT5B MTOR FGFR2 ERBB2 CCND1
5
Show member pathways
13.43 TP53 STAT5B PIK3CA FGFR2 ERBB2 CCND1
6
Show member pathways
13.03 TP53 STAT5B PIK3CA MTOR CCND1 AKT1
7
Show member pathways
13.03 TP53 PIK3CA MTOR FGFR2 ERBB2 CCND1
8
Show member pathways
12.94 STAT5B PIK3CA CCND1 AR AKT1
9
Show member pathways
12.92 PIK3CA MTOR FGFR2 ERBB2 AKT1
10
Show member pathways
12.84 STAT5B PIK3CA MTOR CCND1 AKT1
11
Show member pathways
12.83 TP53 STAT5B PIK3CA MTOR FGFR2 ERBB2
12
Show member pathways
12.8 TP53 PIK3CA MTOR FGFR2 ERBB2 AKT1
13
Show member pathways
12.79 TP53 PIK3CA MTOR ESR1 ERBB2 AKT1
14
Show member pathways
12.74 STAT5B PIK3CA MTOR CCND1 AKT1
15 12.72 TP53 STAT5B PIK3CA NCOA3 MTOR FGFR2
16
Show member pathways
12.67 TP53 STAT5B PIK3CA ERBB2 AKT1
17
Show member pathways
12.61 TP53 STAT5B PIK3CA MTOR ERBB2 CCND1
18 12.6 TP53 PIK3CA MTOR ERBB2 CCND1 BRCA1
19
Show member pathways
12.57 TP53 PIK3CA MTOR FGFR2 ERBB2 AKT1
20
Show member pathways
12.53 STAT5B PIK3CA MTOR ESR1 ERBB2 CCND1
21
Show member pathways
12.52 TP53 PIK3CA MTOR CCND1 AKT1
22
Show member pathways
12.51 TP53 PIK3CA MTOR FGFR2 ERBB2 AKT1
23
Show member pathways
12.49 STAT5B PIK3CA MTOR CCND1 AKT1
24
Show member pathways
12.49 TP53 STAT5B PIK3CA NCOA3 MTOR FGFR2
25
Show member pathways
12.48 PIK3CA MTOR FGFR2 AKT1
26
Show member pathways
12.46 PIK3CA ESR1 BRCA1 AKT1
27
Show member pathways
12.46 TP53 STAT5B PIK3CA MTOR CCND1 AKT1
28 12.44 TP53 STAT5B PIK3CA CCND1 AKT1
29
Show member pathways
12.43 PIK3CA PGR AR AKT1
30
Show member pathways
12.38 PIK3CA NCOA3 ESR1 ERBB2 CCND1 AKT1
31 12.36 TP53 STAT5B PIK3CA CCND1
32
Show member pathways
12.36 TP53 PIK3CA PGR NCOA3 MTOR FGFR2
33
Show member pathways
12.33 TP53 CCND1 BRCA1 AKT1
34
Show member pathways
12.32 TP53 STAT5B MTOR AKT1
35
Show member pathways
12.31 PGR NCOA3 ESR1 CCND1 BRCA1
36 12.31 TP53 PIK3CA MTOR ESR1 ERBB2 CCND1
37 12.27 STAT5B NCOA3 MTOR ERBB2 AKT1
38
Show member pathways
12.25 PIK3CA MTOR FGFR2 AKT1
39
Show member pathways
12.25 TP53 PIK3CA MTOR AKT1
40 12.25 TP53 PIK3CA MTOR CCND1 AKT1
41
Show member pathways
12.22 TP53 PIK3CA MTOR AKT1
42
Show member pathways
12.22 TP53 PIK3CA MTOR FGFR2 ERBB2 CCND1
43
Show member pathways
12.17 PIK3CA MTOR ERBB2 CCND1 AR AKT1
44
Show member pathways
12.16 PIK3CA MTOR FGFR2 BRCA1 AKT1
45
Show member pathways
12.12 TP53 PIK3CA ERBB2 AKT1
46 12.1 TP53 PIK3CA MTOR FGFR2 ERBB2 CCND1
47 12.06 TP53 MTOR CCND1 AKT1
48 12.06 TP53 PIK3CA ERBB2 CCND1 AKT1
49 12.04 PIK3CA MTOR ERBB2 AKT1
50
Show member pathways
12.02 STAT5B PIK3CA PGR ESR1 ERBB2

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 TP53 STAT5B RAB31 PIK3CA PGR NCOA3
2 nuclear chromatin GO:0000790 9.67 TP53 NCOA3 ESR1 AR
3 protein-containing complex GO:0032991 9.5 TP53 NCOA3 MTOR ESR1 BRCA1 AR
4 nucleoplasm GO:0005654 9.44 TP53 STAT5B PGR NCOA3 MTOR HSPB8
5 cytoplasm GO:0005737 10.17 TP53 STAT5B PIK3CA PGR NCOA3 MTOR
6 nucleus GO:0005634 10.1 TP53 STAT5B PGR NCOA3 MTOR HSPB8

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 FGFR2 CCND1 AR AKT1
2 regulation of apoptotic process GO:0042981 9.99 TP53 ESR1 BRCA1 AKT1
3 protein deubiquitination GO:0016579 9.98 TP53 ESR1 BRCA1 AR
4 protein phosphorylation GO:0006468 9.95 PIK3CA MTOR HSPB8 FGFR2 ERBB2 CCND1
5 positive regulation of protein phosphorylation GO:0001934 9.91 MTOR ERBB2 CCND1 AKT1
6 cytokine-mediated signaling pathway GO:0019221 9.91 TP53 STAT5B PIK3CA CCND1 AKT1
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.9 PGR ESR1 CCND1 AR
8 protein autophosphorylation GO:0046777 9.89 MTOR FGFR2 ERBB2 AKT1
9 wound healing GO:0042060 9.87 MTOR FGFR2 ERBB2
10 response to estrogen GO:0043627 9.83 ESR1 CCND1 BRCA1
11 cellular response to growth factor stimulus GO:0071363 9.8 STAT5B ERBB2 AKT1
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 MTOR FGFR2 AKT1
13 steroid hormone mediated signaling pathway GO:0043401 9.78 PGR ESR1 AR
14 cellular response to epidermal growth factor stimulus GO:0071364 9.76 STAT5B ERBB2 AKT1
15 response to estradiol GO:0032355 9.76 STAT5B FOXA1 ESR1 CCND1
16 androgen receptor signaling pathway GO:0030521 9.75 NCOA3 BRCA1 AR
17 positive regulation of protein kinase B signaling GO:0051897 9.72 PIK3CA MTOR FGFR2 ESR1 ERBB2
18 negative regulation of apoptotic process GO:0043066 9.7 TP53 AKT1
19 phosphatidylinositol 3-kinase signaling GO:0014065 9.7 PIK3CA ERBB2 AKT1
20 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.69 TP53 BRCA1
21 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.68 FOXA1 AR
22 multicellular organism growth GO:0035264 9.68 MTOR AR
23 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.67 TP53 ESR1
24 Leydig cell differentiation GO:0033327 9.67 CCND1 AR
25 negative regulation of cell size GO:0045792 9.67 MTOR AKT1
26 reproductive structure development GO:0048608 9.66 FGFR2 AR
27 mitotic G1 DNA damage checkpoint GO:0031571 9.65 TP53 CCND1
28 regulation of glycogen biosynthetic process GO:0005979 9.65 MTOR AKT1
29 prostate gland growth GO:0060736 9.64 CYP19A1 AR
30 prostate gland epithelium morphogenesis GO:0060740 9.63 FOXA1 AR
31 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.62 FGFR2 ESR1
32 mammary gland alveolus development GO:0060749 9.61 ESR1 CCND1 AR
33 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.56 PGR AR
34 response to UV-A GO:0070141 9.55 CCND1 AKT1
35 prostate epithelial cord elongation GO:0060523 9.54 FGFR2 ESR1
36 negative regulation of macroautophagy GO:0016242 9.54 PIK3CA MTOR AKT1
37 positive regulation of gene expression GO:0010628 9.5 TP53 NCOA3 MTOR ERBB2 BRCA1 AR
38 regulation of multicellular organism growth GO:0040014 9.48 STAT5B PIK3CA
39 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.34 ESR1
40 anoikis GO:0043276 9.33 PIK3CA MTOR AKT1
41 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 TP53 STAT5B PGR NCOA3 FOXA1 FGFR2
42 positive regulation of transcription by RNA polymerase III GO:0045945 9.26 MTOR AR
43 phosphatidylinositol phosphorylation GO:0046854 9.19 PIK3CA
44 negative regulation of transcription by RNA polymerase II GO:0000122 10.14 TP53 FOXA1 FGFR2 ESR1 CCND1 AR
45 positive regulation of transcription, DNA-templated GO:0045893 10.04 TP53 NCOA3 ESR1 BRCA1 AR AKT1
46 cell differentiation GO:0030154 10 TP53 NUS1 FOXA1 AKT1

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.93 PIK3CA MTOR FGFR2 ERBB2 CCND1 AKT1
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.91 TP53 STAT5B PGR ESR1 AR
3 protein kinase binding GO:0019901 9.89 TP53 MTOR ESR1 CCND1 AKT1
4 transcription regulatory region DNA binding GO:0044212 9.85 TP53 FOXA1 BRCA1 AR
5 protein kinase activity GO:0004672 9.8 MTOR HSPB8 FGFR2 ERBB2 CCND1 AKT1
6 protein dimerization activity GO:0046983 9.78 STAT5B NCOA3 ERBB2 AR
7 transcription factor binding GO:0008134 9.77 TP53 FOXA1 ESR1 CCND1 AR
8 identical protein binding GO:0042802 9.76 TP53 PGR MTOR HSPB8 ESR1 ERBB2
9 ATPase binding GO:0051117 9.73 PGR ESR1 AR
10 steroid hormone receptor activity GO:0003707 9.61 PGR ESR1 AR
11 nuclear receptor activity GO:0004879 9.58 PGR ESR1 AR
12 nitric-oxide synthase regulator activity GO:0030235 9.54 ESR1 AKT1
13 steroid binding GO:0005496 9.43 PGR ESR1 AR
14 enzyme binding GO:0019899 9.17 TP53 PGR ESR1 CCND1 BRCA1 AR
15 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.65 PIK3CA
16 protein binding GO:0005515 10.48 TP53 STAT5B PIK3CA PGR NUS1 NCOA3
17 transferase activity GO:0016740 10.13 PIK3CA NUS1 NCOA3 MTOR FGFR2 ERBB2
18 DNA-binding transcription factor activity GO:0003700 10.04 TP53 STAT5B PGR FOXA1 ESR1 AR

Sources for Estrogen-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....